Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
1.700
-0.400 (-19.05%)
Nov 16, 2026, 4:00 PM EST - Market closed

Aligos Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
33.652.193.9515.5313.914.36
Revenue Growth
1171.58%-44.59%-74.60%11.66%219.04%-
Cost of Revenue
69.4569.4570.2773.0485.08104.15
Gross Profit
-35.81-67.27-66.32-57.51-71.17-99.79
Selling, General & Admin
22.8420.7222.8329.8926.4128.53
Research & Development
13.88-----
Operating Expenses
36.7220.7222.8329.8926.4128.53
Operating Income
-72.52-87.99-89.15-87.4-97.58-128.32
Interest & Investment Income
2.162.161.674.31.520.24
Currency Exchange Gain (Loss)
0.20.2--0.05-0.04-0.01
Other Non Operating Income (Expenses)
7.3661.74-43.4-3.010.16-0.1
EBT Excluding Unusual Items
-62.8-23.88-130.88-86.16-95.94-128.19
Asset Writedown
----0.72--
Pretax Income
-62.8-23.88-130.88-86.88-95.94-128.19
Income Tax Expense
3.480.310.330.80.110.14
Net Income
-66.29-24.19-131.21-87.68-96.05-128.33
Net Income to Common
-66.29-24.19-131.21-87.68-96.05-128.33
Net Income Growth
------
Shares Outstanding (Basic)
10106322
Shares Outstanding (Diluted)
10106322
Shares Change
17.65%57.79%144.38%50.10%7.12%299.03%
EPS (Basic)
-6.36-2.45-20.94-34.20-56.24-80.50
EPS (Diluted)
-6.37-2.45-20.94-34.20-56.25-80.50
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-68.66-82.94-80.87-79.02-80.33-116.55
Free Cash Flow Per Share
-6.59-8.39-12.91-30.82-47.04-73.11
Operating Margin
-215.55%-4024.93%-2259.92%-562.84%-701.66%-2943.82%
Profit Margin
-197.01%-1106.72%-3326.01%-564.62%-690.63%-2944.07%
Free Cash Flow Margin
-204.07%-3794.15%-2050.01%-508.83%-577.64%-2673.87%
EBITDA
-71.41-87.06-88.13-85.84-95.27-125.3
D&A For EBITDA
1.110.931.031.562.313.02
EBIT
-72.52-87.99-89.15-87.4-97.58-128.32
SEC Filings: 10-K · 10-Q